R-848
| Code | Size | Price |
|---|
| AG-CR1-3582-M005 | 5 mg | £70.00 |
Quantity:
| AG-CR1-3582-M025 | 25 mg | £250.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
Resiquimod; S 28463; R848
Appearance:
White to off-white powder.
CAS:
144875-48-9
EClass:
32160000
Form (Short):
liquid
Handling Advice:
After reconstitution, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
InChi:
InChI=1/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)/f/h18H2
InChiKey:
BXNMTOQRYBFHNZ-DZQCGVKKCS
Long Description:
Chemical. CAS: 144875-48-9. Formula: C17H22N4O2. MW: 314.4. Synthetic. Immune response modifier. Potent antitumor and antiviral compound. Stimulates antibody secretion and cytokine production. Used as adjuvant to increase the effectiveness of vaccines. Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human. Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-kappaB. NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I. Upregulator of the opioid growth factor receptor. Used in the treatment of skin lesions such as herpes simplex virus.
MDL:
MFCD00937759
Molecular Formula:
C17H22N4O2
Molecular Weight:
314.4
Package Type:
Vial
Product Description:
Immune response modifier. Potent antitumor and antiviral compound [1, 3, 10, 11, 13, -16]. Stimulates antibody secretion and cytokine production [2]. Used as adjuvant to increase the effectiveness of vaccines [2, 7, 9, 10]. Potent and selective synthetic ligand for Toll-like receptor 7 (TLR7) in mouse and for TLR7 and TLR8 in human [4-6]. Activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway and leads to the induction of NF-kappaB [4]. NLRP3/NALP3 inflammasome activator, independent of TLRs and RIG-I [8]. Upregulator of the opioid growth factor receptor [12]. Used in the treatment of skin lesions such as herpes simplex virus [16].
Purity:
>98%
SMILES:
CCOCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N
Solubility Chemicals:
Soluble in DMSO, dichloromethane or methanol. Slightly soluble in acetonitrile or ethyl acetate.
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C.
References
Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod: T.L. Wagner, et al.; Cell Immunol. 191, 10 (1999) | Adjuvant activities of immune response modifier R-848: comparison with CpG ODN: J.P. Vasilakos, et al.; Cell Immunol. 204, 64 (2000) | The immune response modifier resiquimod mimics CD40-induced B cell activation: G.A. Bishop, et al.; Cell. Immunol. 208, 9 (2001) | Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002) | Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848: M. Jurk, et al.; Nat. Immunol. 3, 499 (2002) | Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8: K.B. Gorden, et al.; J. Immunol. 174, 1259 (2005) | TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848): R.D. Weeratna, et al.; Vaccine 23, 5263 (2005) | Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3: T.D. Kanneganti, et al.; Nature 440, 233 (2006) | Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination: R. Ma, et al.; BBRC 361, 537 (2007) | Resiquimod and other immune response modifiers as vaccine adjuvants: M.A. Tomai, et al.; Expert Rev. Vaccines 6, 835 (2007) (Review) | The antiviral activity of Toll-like receptor 7 and 7/8 agonists: R.L. Miller, et al.; Drug News Perspect. 21, 69 (2008) (Review) | Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function: I.S. Zagon, et al.; Exp. Biol. Med. 233, 968 (2008) | Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation: W. van den Ancker, et al.; Cancer Immunol. Immunother. 60, 37 (2011) | Treatment with the TLR7 agonist R848 induces regulatory T-cell-mediated suppression of established asthma symptoms: L.P. Van, et al.; Eur. J. Immunol. 41, 1992 (2011) | R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes: H. Nian, et al.; BMC Infect. Dis. 12, 5 (2012) | Resiquimod|a topical drug for viral skin lesions and skin cancer: T. Meyer, et al.; Expert Opin. Investig. Drugs 22, 149 (2013) | TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother. 62, e02417 (2018) | Systemic and intestinal porcine epidemic diarrhea virus-specific antibody response and distribution of antibody-secreting cells in experimentally infected conventional pigs: Vet. Res. 52, 2 (2021)
Related Products
| Product Name | Product Code | Supplier | Imiquimod | AG-CR1-3569 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|